Amendments to the Transitional Provisions of the European Union MDR and IVDR
The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device - until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

The Proposal Amendments

The proposal has 3 articles:

  • Article 1 – Amendments to Article 120(2), (3) and (4) and to Articles 122 and 123 of the MDR.
  • Article 2 – Amendments to Article 110(4) and to Article 112 of the IVDR.
  • Article 3 – Entry into force and application

Amendments to MDR

Transition period extension

The validity of the certificates issued under the Directives that were valid on 26 May 2021 was extended. If the certificates have already expired when the proposed amendment enters into force, the extension is only applicable if the manufacturer has a signed contract with a notified body for the conformity assessment at time of the expiry.

The transition period is extended until 31 December 2027 for higher risk devices (class III and class IIb implantable devices) and until 31 December 2028 for medium and lower risk devices (other class IIb devices and class IIa, class Im, Is and Ir devices).

The amendment also introduces a transition period until 26 May 2026 for class III custom-made implantable devices.

Conditions for the transition period

The extended transition period applies only to ‘legacy devices’.

Moreover, the application of the extended transition period is subject to the following cumulative conditions:

  • The devices must continue to comply with the Directives
  • The devices do not significantly change their design and intended purpose
  • The devices do not present an unacceptable risk to the health or safety of patients, users, other persons, or public health
  • No later than 26 May 2024, the manufacturer has put in place a quality management system (QMS) according to the MDR.
  • No later than 26 May 2024, the manufacturer has lodged a formal application for conformity assessment according to MDR, and no later than 26 September 2024 the notified body and the manufacturer have signed a written agreement

The devices covered by a certificate issued according to the Directives remain subject to appropriate surveillance by the notified body that issued the certificate. However, the manufacturer can agree that this becomes responsibility of the notified body designated under the MDR.

Deletion of the sell-off provision

Devices placed on the market before the end of the transition period can be made further available on the market without a legal time restriction.

Amendments to IVDR

Devices placed on the market before the end of the transition period (May 26 2027 for class A sterile and B, May 26 2026 for class C and May 26 2025 for class D) can be made further available on the market without a legal time restriction.

If you wish to get more information about the provisions of the EU-MDR and the EU-IVDR, feel free to contact us at info@criticalcatalyst.com.

European Commission Full Proposal

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »